23 / 33
•
BRCAness profile is now beyond mutations in BRCA germline
•
This profile predicts platinum and PARPi sensitivity and better clinical outcomes
•
BRCA testing in the germline and in the tumor expands up to 20% the number of patients
who would benefit from targeted treatments
•
Ideally, patients should be tested at diagnosis
•
The validation of HRD assays and multiple gene sequencing panels to guide treatment selection
is under evaluation
•
Recent data from clinical trials with PARPi (NOVA trial, ARIEL-3) may have an impact in this line of
research
CONCLUSIONS